| Active substance | Efanesoctocog alfa |
| Holder | Swedish Orphan Biovitrum (Sobi) |
| Status | Running |
| Indication | Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 10/09/2024 |